What is SCLX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SCLX?

P/E (TTM) is n/a and 52-week range is $2.27 to $27.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SCLX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SCLX?

The company profile lists revenue (TTM) near $39M, net income (TTM) near -$55.08B, EPS (TTM) near -$48.45 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Scilex Holding Co based, and what identifiers does Chartloom list?

The company context section lists headquarters in Palo Alto, California, US, 8.5M shares outstanding, ISIN US80880W2052 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Scilex Holding Co

$SCLX

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 34 full-time employees. The company went IPO on 2021-01-11. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.

Employees

Website

www.scilexholding.com/

IPO

2021-01-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US80880W2052

Headquarters

Palo Alto, California, US

Shares outstanding

8.5M

NAICS sector

Manufacturing

Institutional ownership

8.53%

Browse other companiesFree AI scores and summaries for more stocks